2 November 2017

Clinigen Group plc

Admission of Consideration Shares

and

Notice of Total Voting Rights

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global pharmaceutical and services company, is pleased to announce that, further to Clinigen's and Quantum Pharma Plc's ("Quantum") announcement on 1 November 2017 that the scheme of arrangement under Part 26 of the Companies Act 2006 to effect the recommended acquisition of Quantum by Clinigen has become effective, 6,849,264 new ordinary shares of 0.1p each in the Group have now been admitted to trading on AIM at 8.00 a.m. this morning.

The Group's issued share capital now comprises 122,220,024 ordinary shares of 0.1p each, with no shares held in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Group under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

- Ends -

Contact Details:

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com